Drugs / ADRX-0405
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06710379 | Dec 2024 → Jul 2026 overdue | cancer | Adcentrx Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-08 | Adcentrx Therapeutics | Regulatory China NMPA Grants IND Clearance to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer adcentrx.com ↗
Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company advancing Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the China National Medical Products Administration (NMPA) has cleared Adcentrx’s Investigational New Drug (IND) application for ADRX-0405. |
| 2025-07-08 | Adcentrx Therapeutics | Regulatory U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX‑0405 STEAP1 ADC for Gastric Cancer adcentrx.com ↗
Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADRX-0405, for the treatment of patients with gastric cancer. |
| 2024-10-21 | Adcentrx Therapeutics | Regulatory Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors adcentrx.com ↗
Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company advancing innovative protein conjugates for cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application of ADRX-0405 for the treatment of select advanced solid tumors. |
All press releases naming this drug 4 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADRX-0405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06710379 ↗ |